These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 11935215)

  • 1. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
    Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
    Jhaveri KD; Flombaum C; Shah M; Latcha S
    J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of the major metabolites of capecitabine.
    Gieschke R; Reigner B; Blesch KS; Steimer JL
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
    Reigner B; Clive S; Cassidy J; Jodrell D; Schulz R; Goggin T; Banken L; Roos B; Utoh M; Mulligan T; Weidekamm E
    Cancer Chemother Pharmacol; 1999; 43(4):309-15. PubMed ID: 10071982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
    Chachad S; Purandare S; Malhotra G; Naidu R
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):287-92. PubMed ID: 23090620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
    Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
    Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
    Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B
    Clin Cancer Res; 1999 Jul; 5(7):1696-702. PubMed ID: 10430071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.